Florida is currently home to 3770 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Miami, Tampa, Jacksonville and Orlando. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP
Recruiting
This study will evaluate and compare the safety, efficacy, and tolerability of 2 doses of a recombinant adeno-associated virus vector (AGTC-501/laruparetigene zovaparvovec )) to an untreated control group in male participants with X-linked retinitis pigmentosa caused by RPGR mutations.
Gender:
MALE
Ages:
Between 12 years and 50 years
Trial Updated:
05/16/2025
Locations: University of Florida Health Jacksonville, Department of Ophthalmology, Jacksonville, Florida
Conditions: X-Linked Retinitis Pigmentosa
Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment
Recruiting
This phase I/II trial investigates the best dose, possible benefits and/or side effects of tazemetostat in combination with dabrafenib and trametinib in treating patients with melanoma that has a specific mutation in the BRAF gene (BRAFV600) and that has spread from where it first started (primary site) to other places in the body (metastatic). Tazemetostat, dabrafenib, and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving tazemetostat i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: UM Sylvester Comprehensive Cancer Center at Aventura, Aventura, Florida
Conditions: Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma
Mechanisms and Modulation of Pain Modulatory Capacity
Recruiting
This project proposes to understand the sources of pain variability, and demonstrate that pain variability represents fluctuation in natural pain management. The project further proposes to determine if endogenous capacity to modulate pain can be trained to maximize their body's ability to manage pain, much as the way in which athletic performance can be trained.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
05/16/2025
Locations: Unversity of Florida, Gainesville, Florida
Conditions: Musculoskeletal Pain
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
Recruiting
This is a Phase 3, open-label, single arm trial designed to evaluate Cretostimogene patients with NMIBC who have failed prior BCG therapy. Up to approximately 115 CIS bladder cancer patients with or without HG Ta or HG T1 papillary disease will be enrolled under the original protocol through Amendment 4, which will comprise Cohort C. Cohort C is closed to enrollment. Under Amendment 5-1, Cohort P was added to enroll up to 70 patients with HG Ta/T1 papillary bladder cancer. Under Amendment 6, t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: Mayo Clinic - Jacksonville, Jacksonville, Florida
Conditions: Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer
Systemic Hypothermia in Acute Cervical Spinal Cord Injury
Recruiting
This study is a prospective multi-center trial designed to determine the safety profile and efficacy of modest (33ºC) intravascular hypothermia following acute cervical (C1 to C8) Spinal Cord Injury (SCI).
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
05/16/2025
Locations: Jackson Memorial Hospital, Miami, Florida
Conditions: Spinal Cord Injury, Acute
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Recruiting
DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progression free survival (PFS), as assessed by BICR, in participants with HER2-expressing (IHC 3+/2+), pMMR, primary advanced (Stage III/IV) or recurrent EC.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/15/2025
Locations: Research Site, Fort Myers, Florida
Conditions: Endometrial Cancer
A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)
Recruiting
Narcolepsy without cataplexy or Narcolepsy Type 2 (NT2) is a lifelong condition that makes people very sleepy during the day, regardless of how much sleep they get at night. People with NT2 may fall asleep suddenly, have trouble staying awake during the day, or may not be able to sleep well at night. They may have difficulty thinking clearly, paying attention, or remembering things, during the day. These symptoms can make daily activities like driving, working, or caring for their families chall... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
05/15/2025
Locations: Takeda Site 13, Brandon, Florida
Conditions: Narcolepsy Type 2
Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)
Recruiting
The main purpose of this study is to investigate efficacy and safety of three doses of petrelintide versus placebo in participants with overweight or obesity and type 2 diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/15/2025
Locations: Innovative Research of West Florida, Clearwater, Florida
Conditions: Overweight, Type 2 Diabetes, Obesity
Sweet Corn and Carotenoids
Recruiting
This study will assess the effect of daily yellow and white sweet corn intake on serum lutein and zeaxanthin concentrations. Skin carotenoid levels using the Veggie Meter will be assessed, and gastrointestinal symptoms and changes in fecal microbiota during a 4-week intervention period will be monitored.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
05/15/2025
Locations: University of Florida, Gainesville, Florida
Conditions: Carotenoids
Pulsed Electromagnetic Field Treatment With Dementia Patients
Recruiting
An open label pilot study in mild to moderate AD/ADRD patients to assess the effects of treatment with ECHS AD/ADRD pulsed electromagnetic treatment device on disease progression. Enrolled patients will receive active devices. They will treat themselves at home three times a day for 15 minutes over 120 days. Primary end point is the The Alzheimer's Disease Assessment Scale-Cognitive Subscale. Participants will be followed-up for 9 months post-treatment.
Gender:
ALL
Ages:
Between 50 years and 100 years
Trial Updated:
05/15/2025
Locations: University of Miami, Boca Raton, Florida
Conditions: Alzheimer's Disease, Lewy Body Dementia, Vascular Dementia
Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004
Recruiting
This is a Phase I, multicentre, single-dose, non-randomised, open-label, parallel-group study to examine the PK, safety, and tolerability of AZD5004 in male and female participants with mild, moderate, and severe hepatic impairment compared with participants with normal hepatic function.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/15/2025
Locations: Research Site, Orlando, Florida
Conditions: Hepatic Impairment
Safety, Effectiveness, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Recruiting
This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to histological subtypes due to differences in chemotherapy choice for standard-of-care and type of NSCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/15/2025
Locations: Clermont Oncology Center, Clermont, Florida
Conditions: Non-small Cell Lung Cancer